+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID06452316

Open-Label Study of CSB-001 Ophthalmic Solution 0.1% for Treating Limbal Stem Cell Deficiency

Led by Claris Biotherapeutics, Inc. · Updated on 2026-08-13

75

Participants Needed

6

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

This research aims to evaluate the safety and effectiveness of CSB-001 Ophthalmic Solution 0.1% in people with limbal stem cell deficiency LSCD. It is an open-label Phase 1 study sponsored by Claris Biotherapeutics, Inc. Participants will receive the investigational drug in one or both eyes to investigate its impact on this eye condition. The study includes two dosing phases separated by a break and a long-term follow-up period. Participants will receive one drop of CSB-001 four times daily during two 8-week dosing periods separated by a 31- to 40-day dosing holiday where no drug is given. These dosing phases are followed by an observational phase lasting up to Week 48. After this, participants may choose to join an additional 36-month observational extension phase to Week 144. The study is non-randomized and open-label, meaning all participants receive the study drug. During the study, participants will be assessed regularly for safety using adverse event reporting, slit-lamp biomicroscopy, and vision tests through Week 144. Effectiveness will be measured by changes in LSCD stage and vision clarity. Study visits will include clinical examinations and eye imaging. Safety and vision will be monitored throughout the treatment and observation periods to understand the drugs impact over time.

CONDITIONS

Brief Title

Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Limbal Stem Cell Deficiency

Research Team

C

Central Operations Representative

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here